Any current/future new fundraising through debt or equity?

The transcript does not explicitly mention any current or planned fundraising through debt or equity. However, the company is undertaking significant capital expenditure of about INR125 crores over the next 1-2 years, primarily for new plant setups and expansions. Investments include a new automated plant in Rajasthan and expansion in Dahej, focusing on increasing production capacity. Management emphasizes improving working capital cycles but does not indicate raising funds through external equity or debt in this call. The acquisition of Kaeros was for INR6.3 crores, done through internal mean

Any current/future capex/capital investment/strategic investment?

Significant capex underway at Sotanala (Rajasthan) and Dahej plants. Sotanala plant: includes formulation and technical manufacturing; target to start production in 2026. Dahej plant formulation expected to start by mid-2025 season (around June). Total capex planned around INR 125 crores over next 2 years, majority to be spent in next fiscal year. Expansion includes setting up a DCS plant with formulation facilities for liquids and other products on 15 acres. Investment in IIL Biologicals with large land purchased for future growth in biological products. Strategic acquisition of Kaeros (~INR

Future growth expectations in sales/revenue/volumes?

Targeting minimum 20% year-on-year growth in premium (B2C) products, particularly Maharatna segment. Vision to increase premium product contribution to 65% of B2C sales within 1-2 years. Overall B2C volume growth reported around 19% in recent 9 months; value growth about 12%. Continuous launch of new profitable products, with 6-10 product launches planned annually. Expanding distributor network by approximately 4-5% and enhancing retailer/farmer engagement via CRM and digital tools. Planned operationalization of a new automated plant by 2026 expected to generate INR 500 crores in volumes at 70

Future growth expectations in earnings/operating earnings/profits/EPS?

Targeting minimum 20% year-on-year growth in premium B2C segment volumes, especially focused on Maharatna products. Aim to increase premium product sales contribution to 65% within 1-2 years, enhancing margins and profitability. EBITDA margin expected to be maintained around 12%-13%, with gross margins targeted between 30%-35% in the next 1-2 years. Highest-ever PAT recorded so far with 35% growth compared to previous year, indicating strong earnings momentum. New automated plant in Rajasthan planned to start operations in 2026, expected to generate volume INR 500 crores at 70% capacit

Current/ Expected Orderbook/ Pending Orders?

The transcript does not explicitly mention the current or expected order book or pending orders for Insecticides India Limited. However, there is discussion on significant growth plans, including: - Targeting 20% year-on-year growth in the premium B2C segment. - Launching at least 6 new products in the next fiscal year. - Setting up a new automated plant in Rajasthan expected to start operations in 2026, which will enhance production capacity. - Expansion in biological products expected to contribute significantly over the medium term. - Ongoing partnerships and acquisitions (e.g., K

IN US

Sale is live|00:00:00left today

Insecticides India LtdQ4 FY26Fertilizers & Agrochemicals

Insecticides India Ltd Q4 FY26 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹669P/E: 14.8Market Cap: ₹2.1K CrSector: Fertilizers & Agrochemicals

Management growth scorecard

Revenue

Category 2

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 2

→Targeting minimum 20% year-on-year growth in premium (B2C) products, particularly Maharatna segment.
→Vision to increase premium product contribution to 65% of B2C sales within 1-2 years.
→Overall B2C volume growth reported around 19% in recent 9 months; value growth about 12%.
→Continuous launch of new profitable products, with 6-10 product launches planned annually.
→Expanding distributor network by approximately 4-5% and enhancing retailer/farmer engagement via CRM and digital tools.
→Planned operationalization of a new automated plant by 2026 expected to generate INR 500 crores in volumes at 70% capacity.
→Export growth targeted above INR 100 crores with potential for further increase driven by registrations and improved business.
→Incremental marketing spend and strengthening organization aimed at sustained growth across B2C, B2B, and export segments.

Margin guidance

Category 3

→Targeting minimum 20% year-on-year growth in premium B2C segment volumes, especially focused on Maharatna products.
→Aim to increase premium product sales contribution to 65% within 1-2 years, enhancing margins and profitability.
→EBITDA margin expected to be maintained around 12%-13%, with gross margins targeted between 30%-35% in the next 1-2 years.
→Highest-ever PAT recorded so far with 35% growth compared to previous year, indicating strong earnings momentum.
→New automated plant in Rajasthan planned to start operations in 2026, expected to generate volume INR 500 crores at 70% capacity, aiding capacity and cost structure.
→Continuous launches of profitable premium products with no gestation period; new products immediately contribute to profits.
→Working capital improvements targeted to reduce cycle by 20-25 days, supporting operational efficiency and earnings.
→Export business expected to grow steadily from INR 100 crores+ currently, adding to future earnings growth.

3 more insights locked — sign up free to unlock

Fundraise plans

→The transcript does not explicitly mention any current or planned fundraising through debt or equity.
→However, the company is undertaking significant capital expenditure of about INR125 crores over the next 1-2 years, primarily for new plant setups and expansions.
→Investments include a new automated plant in Rajasthan and expansion in Dahej, focusing on increasing production capacity.
→Management emphasizes improving working capital cycles but does not indicate raising funds through external equity or debt in this call.
→The acquisition of Kaeros was for INR6.3 crores, done through internal means (valuation-based), with no mention of external fundraising for this transaction.
→Overall, no direct comments on future debt or equity fundraising were disclosed during this earnings call.

Order book

→The transcript does not explicitly mention the current or expected order book or pending orders for Insecticides India Limited.
→However, there is discussion on significant growth plans, including:
→ - Targeting 20% year-on-year growth in the premium B2C segment.
→ - Launching at least 6 new products in the next fiscal year.
→ - Setting up a new automated plant in Rajasthan expected to start operations in 2026, which will enhance production capacity.
→ - Expansion in biological products expected to contribute significantly over the medium term.
→ - Ongoing partnerships and acquisitions (e.g., Kaeros) aimed at increasing technical imports and improving profitability.
→While no numeric order backlog figures are shared, management expresses confidence in continued growth and scaling up capacity and product launches to meet market demand.

Capex plans

Yes

→Significant capex underway at Sotanala (Rajasthan) and Dahej plants.
→Sotanala plant: includes formulation and technical manufacturing; target to start production in 2026.
→Dahej plant formulation expected to start by mid-2025 season (around June).
→Total capex planned around INR 125 crores over next 2 years, majority to be spent in next fiscal year.
→Expansion includes setting up a DCS plant with formulation facilities for liquids and other products on 15 acres.
→Investment in IIL Biologicals with large land purchased for future growth in biological products.
→Strategic acquisition of Kaeros (~INR 6.3 crores) for import licenses and supply chain advantage, aiming INR 100+ crores business with double-digit margins.
→Continuous investment in market, facilities, systems, and talent to strengthen B2C business growth.

How does Insecticides India Ltd rank vs peers in Fertilizers & Agrochemicals?

Pro feature

1Insecticides India Ltd

Rev 2Mar 3

See full Fertilizers & Agrochemicals sector rankings

Want more stocks like Insecticides India Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio